MOONLAKE IMMUNOTHERAPEUTICS MLTX
COM · Common Stock · CUSIP G4444C102
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
1
institutional holders
+0 vs Q1 2024
166.6k
shares reported held*
$7.3mreported value*
0 new
0 added
0 reduced
0 sold out
net bought ≈ $0
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $43.97.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2024 | 1 |
| Q2 2024 | 1 |
Insider purchases and sales in Q2 2024
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
BuyingSelling
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2022 | 0 | — | 0 | — | — |
| Q4 2022 | 0 | — | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 0 | — | 0 | — | — |
| Q3 2023 | 0 | — | 0 | — | — |
| Q4 2023 | 0 | — | 1 | $5.9m | $5.9m |
| Q1 2024 | 0 | — | 2 | $21.8m | $21.8m |
| Q2 2024 | 0 | — | 0 | — | — |
None reported in Q2 2024.
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| Decheng Capital LLC 2.24% of their portfolio | 166.6k $7.3m | Unchanged |